Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04251416
Title A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Alessandro Santin
Indications

endometrial carcinoma

Therapies

Sacituzumab govitecan-hziy

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.